مولانا عبدالسمیع
گزشتہ ماہ کاالم ناک سانحہ دارالعلوم دیوبند کے قدیم تر استاذ حضرت مولانا عبدالسمیع صاحب ؒ کی وفات ہے۔مولانا مرحوم کئی ماہ سے علالت کے امتداد واشتداد کی تکلیفیں اٹھا رہے تھے، بالآخر ۱۰/صفر المظفرکو ہمیشہ کے لیے اس جہان فانی سے رخصت ہوگئے۔
مرحوم حضرت مولانا میاں سید اصغر حسین صاحبؒ کے مخصوص ہم سبقوں میں تھے اوربزرگوں کی خوبیوں اورخصوصیتوں کے جامع، بڑے با وضع، بڑے سادہ مزاج اوردارالعلوم کے اساتذہ میں بعض اوصاف کے لحاظ سے بے عدیل و بے مثیل۔ پیرانہ سالی اورغیر معمولی نقاہت کے باوجود جب درس دیتے تھے تو معلوم ہوتا تھا کوئی تازہ دم اور بلندآواز مدرس پورے شوق و انہماک کے ساتھ طلبہ سے مصروف تخاطب ہے۔ مولانا کا طرزتعلیم عام فہم بھی تھا اوردل پذیر بھی، پڑھاتے پڑھاتے بہت سی کتابوں کے حافظ ہوگئے تھے۔اُن کے تلامذہ میں آج بڑے بڑے مدرس بھی ہیں اورباکمال مصنف اورانشاء پرداز بھی۔ ندوۃ المصنفین کے تقریباً تمام بڑے بڑے رفقاء کوآپ سے شرف تلمذ حاصل ہے۔اﷲ تعالیٰ مرحوم کے مراتب بلند فرمائے۔ہمیں اس حادثۂ عظیم میں مولانا مرحوم کے اکلوتے صاحبزادے مولوی عبدالاحد صاحب مدرس دارالعلوم دیوبند سے دلی ہمدردری ہے اورہم اُن کے شریک غم ہیں۔ امید ہے مولوی صاحب موصوف اپنے والد کے صحیح قائم مقام ثابت ہوں گے۔ [فروری ۱۹۴۷ء]
Man is always trying to make his life easier and accomplished. He has faced mass destruction in history due to epidemics like small pox, malaria and plague. In order to combat diseases, exploration of man led him to search for causative agents and their control. A time reached when it was found that microbes are themselves a source of potent metabolites which have proved to be effective as drugs and medicines showing great antibiotic activity. It is necessary to find out new sources for potential new antimicrobial compounds. Several hundred important compounds have been isolated which have antibiotic activities and diverse chemical nature. But these compounds should have minimum toxicity to be useful clinically. Because of the increasing resistance of pathogens, there was a never ending desire and need to search for more. Bioactive Compounds have been extracted from microbes which are produced as secondary metabolites. Day by day, new compounds are being discovered giving a hope of golden future of drug industry. The current article emphasizes the importance and need to search for new bioactive compoundsto overcome infections caused by multiple drug resistant (MDR) and biofilm forming pathogens irrespective of the previously present knowledge.
INTRODUCTION Tuberculosis is a chronic infectious bacterial disease caused by Mycobacterium tuberculosis. Multi drug resistant tuberculosis is a form of tuberculosis caused by a strain of Mycobacterium tuberculosis complex which are resistant to at least Isoniazid and Rifampicin with or without resistance to any other first line antituberculosis treatment (ATT). Multiple factors have been identified those lead to multi drug resistance response to tuberculosis. Treatment of multi-drug resistant tuberculosis requires treatment with second line drugs, usually four or more TB drugs for a minimum period of 6 months and probably extending for 18-24 months if rifampicin resistance has been identified. Linezolid is an antibiotic used for the treatment of serious infections caused by gram positive bacteria and in highly resistant tuberculosis strain and cases that are otherwise complicated to treat. OBJECTIVES The objectives of this study were to determine the demographic features of participants in this study, to determine risk factors in multi-drug resistant tuberculosis and to conduct a clinical trial for the determination of efficacy of linezolid in patients with multi drug resistant tuberculosis. Study design; To determine the demographic features of Tuberculosis, cross sectional study, to determine the risk factors in patients with Tuberculosis and multi-drug resistant Tuberculosis, analytical cross sectional study and to conduct the clinical trial for examining the efficacy of Linezolid for treatment of multi drug resistant tuberculosis, clinical trial was conducted by using the study design of experimental epidemiology (Single blind randomized control trial phase-4) Study Universe: Public sector Hospital, Lahore Pakistan. Study population: Tuberculosis and multi-drug resistant tuberculosis patients registered or followed by Outpatient Department of public sector Hospital Lahore Sampling Technique;: Convenient sampling for project-1 & 2 and Simple Random Sampling for project-3 Study Duration: One year (1st Dec 2016 to 30th Nov2017) DATA COLLECTION PROCEDURE; using convenient sampling/simple random sampling technique, data collected through a questionnaire. Subjects from public sector hospital were enrolled in the study according to inclusion and exclusion criteria. They were investigated, examined, monitored and data recorded in a questionnaire. Statistical analysis was done using SPSS version RESULTS; During demographic analysis of patients with tuberculosis, it was observed that female cases were higher than male cases. Age group 18-34 years was maximally affected by tuberculosis. The disease had a decreasing trend with aging. In both genders number of cases was decreasing with increase of age. There were only a few cases above 60 years of age. Majority of cases belonged to Lahore or its suburbs. . Majority of the cases belonged to urban area, had lower class and low socioeconomic status. Males were more educated as compared to females. Majority of the cases were relapsed. Two third cases had extra pulmonary Tuberculosis. In extra pulmonary tuberculosis, majority of cases involved lymph nodes. The risk factors for tuberculosis and multi-drug resistant tuberculosis were not common. In randomized control trial with Linezolid, 90% cases of multi-drug resistant tuberculosis were pulmonary tuberculosis. Treatment with Linezolid proved to be effective in 60% cases. CONCLUSION; In this study analysis of demographic profile showed that the number of female patients was increasing. The age group 18-44 years was maximally affected. In randomized control trial with Linezolid, 90% cases of multidrug resistant tuberculosis were pulmonary. Treatment with Linezolid proved to be effective in 60% cases with multi-drug resistant tuberculosis.